Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...1516171819202122232425...5960»
  • ||||||||||  Journal:  Lifelong excess in GH elicits sexual dimorphic effects on skeletal morphology and bone mechanical properties. (Pubmed Central) -  Sep 8, 2022   
    Female bGH mice preserved their trabecular architecture during aging, while trabecular bone volume in male bGH mice significantly reduced and associated with thinning of the trabeculae. We conclude that pathological excess in GH results in sexual dimorphic changes in bone architecture and gains in bone mass, that affect whole-bone mechanical properties, as well as a sex-specific differences in bone material properties.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  IpoProAcro: Hypoproteic Diet in Acromegaly (clinicaltrials.gov) -  Sep 2, 2022   
    P=N/A,  N=12, Not yet recruiting, 
    We conclude that pathological excess in GH results in sexual dimorphic changes in bone architecture and gains in bone mass, that affect whole-bone mechanical properties, as well as a sex-specific differences in bone material properties. Trial completion date: Dec 2022 --> Mar 2024 | Initiation date: May 2022 --> Jan 2023 | Trial primary completion date: Oct 2022 --> Dec 2023
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Enrollment open:  Korean Regulatory Post Marketing Surveillance for Somavert (clinicaltrials.gov) -  Sep 2, 2022   
    P=N/A,  N=100, Recruiting, 
    Trial completion date: Dec 2022 --> Mar 2024 | Initiation date: May 2022 --> Jan 2023 | Trial primary completion date: Oct 2022 --> Dec 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Association of pre- and postoperative αKlotho levels with long-term remission after pituitary surgery for acromegaly. (Pubmed Central) -  Sep 2, 2022   
    Interestingly, there was a statistically significant difference in pre- and postoperative levels of sKl between the long-term cure group and the group with persistent disease activity. This study provides first evidence that sKl may serve as an additional marker for surgical success, decreasing substantially in all patients with initial clinical remission while remaining high after surgery in patients with persistent disease activity.
  • ||||||||||  Cost-Effectiveness of Lanreotide Atg Verse Octreotide for the Treatment of Acromegaly in China (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1426;    
    We believe cues obtained from the study may be used to generate the metabolite-based test to diagnose PAs from serum in addition to conventional techniques and also to understand disease biology for better disease management, point of care, and improving quality of life in PA patients. At a threshold of 1.5 times Chinese GDP per capita, lanretide-ATG was the dominant treatment strategy compared with octreotide from both of Chinese health system and society perspective
  • ||||||||||  Cost of Illness Study of Acromegaly in Bulgaria - A Real-World Data Analysis (In-person; Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1188;    
    This real-world evidence study is the first one which evaluates the financial burden of concomitant diseases for acromegaly patients in Bulgaria. Despite the pharmacotherapy costs for acromegaly outline the other costs, the Bulgarian patients have an adequate financial access to therapy provided through the existing reimbursement system in the country.
  • ||||||||||  Review, Journal:  Genetic and Epigenetic Pathogenesis of Acromegaly. (Pubmed Central) -  Aug 27, 2022   
    Moreover, recent findings based on multiple perspectives of the pangenomic approach including genome, transcriptome, and methylome analyses, histological characterization, genomic instability, and possible involvement of miRNAs have gradually unveiled the whole landscape of the underlying mechanisms of somatotroph tumors. In this review, we will focus on the recent advances in genetic and epigenetic pathogenesis of somatotroph tumors.
  • ||||||||||  Clinical, Journal:  DIFFERENTIAL DIAGNOSIS OF ACROMEGALY: PACHYDERMOPERIOSTOSIS TWO NEW CASES, TURKEY. (Pubmed Central) -  Aug 27, 2022   
    Such clinical presentation in corroboration with normal growth hormone level and prominent radiological abnormalities prompted us to make a diagnosis of pachydermoperiostosis.Consequently,pachydermoperiostosis is a very rare osteoarthrodermopathic disorder whose clinical and radiographic presentations may mimic those of acromegaly. In the evaluation of patients with acromegaloid appearances, pachydermoperiostosis should be considered as a differential diagnosis.
  • ||||||||||  Review, Journal:  Surgery for acromegaly: Indications and goals. (Pubmed Central) -  Aug 24, 2022   
    Attempted gross total resection of the GH-secreting adenoma is the gold standard in treatment for patients with acromegaly for a goal of biochemical remission. Medical and radiation therapies are available when patients do not achieve biochemical cure after surgical therapy.
  • ||||||||||  Observational data, Journal:  Impact of Diabetes on Morbidity and Mortality in Patients with Acromegaly. (Pubmed Central) -  Aug 24, 2022   
    In patients treated with long-acting SRLs, IGF-I sampling at the farthest distance from SRL injection is the most informative and best predictor of optimal disease control. The presence of diabetes in patients with acromegaly was associated with increased overall mortality as well as increased cardiovascular mortality and morbidity.
  • ||||||||||  Journal:  Increased Risk of Ocular Hypertension in Patients with Cushing's Disease. (Pubmed Central) -  Aug 22, 2022   
    An increased risk of ocular hypertension was seen in CD and suggests that endogenous hypercortisolemia should be considered as part of the glaucoma assessment. This result warrants the discretion of both ophthalmologists and neuroendocrinologists.
  • ||||||||||  octreotide acetate solution for injection / Generic mfg.
    Journal:  Minimizing the initial burst of octreotide acetate based long-acting microspheres by the solvent evaporation method. (Pubmed Central) -  Aug 18, 2022   
    Sandostatin long-acting release (SLAR) depot for 1-month controlled release of octreotide is a somatostatin analogue product that has been used extensively in the pharmacological treatment of acromegaly...Analysis of kinetics of dry Tg of the formulations reflected (a) the elevated residual solvent in SLAR and was not duplicated in the solvent evaporation formulations, and (b) the slightly higher Tg of peptide loaded formulations relative to than blank microspheres, consistent with the interaction of the acetate salt of octreotide with linear PLGA chains in the PLGA-glu. These data indicate that it is possible to prepare peptide loaded microspheres by the solvent evaporation method with extraordinarily similar performance to microspheres, such as those in SLAR, that are prepared by the low-burst release coacervation method.
  • ||||||||||  cabergoline / Generic mfg.
    Review, Journal:  Preoperative Medical Treatment for Patients With Acromegaly: Yes or No? (Pubmed Central) -  Aug 17, 2022   
    The aim of this review is to analyze the potential benefits and pitfalls of using presurgical medical treatment in acromegaly in view of the contradictory literature data. We also attempt to determine the profile of patients who might most benefit from this presurgical medical treatment approach as an individualized therapeutic management of acromegaly.
  • ||||||||||  Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
    MACROGLOSSIA IN THE SETTING OF COVID-19 (Convention Center Exhibit Hall: Poster Area) -  Aug 16, 2022 - Abstract #CHEST2022CHEST_1911;    
    As the effects of COVID-19 are becoming better studied overtime, macroglossia, especially in those with African ancestry, is increasingly coming under the radar. This case report seeks to educate clinicians on this possible sequela and encourage supportive treatment in hopes that the tongue will recover.
  • ||||||||||  Is Bigger Better? Anesthetic Implications Of Acromegaly And Gigantism (Hall C) -  Aug 15, 2022 - Abstract #ASA2022ASA_4301;    
    Cardiac dysfunction manifests as LVH with diastolic/systolic dysfunction secondary to collagen deposition and expression of sarcomere proteins. Hyperglycemia is common secondary to the anti-insulin effects of IGF1.
  • ||||||||||  Transsphenoidal Hypophysectomy For A Patient On Ventricular Assist Device (Hall C) -  Aug 15, 2022 - Abstract #ASA2022ASA_3951;    
    Impella settings were at maximum and patient’s hemodynamics were maintained on several vasopressors and inotropes. After successful pituitary resection patient had permanent biventricular assist device and was maintained on full anticoagulation.
  • ||||||||||  Review, Journal:  Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. (Pubmed Central) -  Aug 14, 2022   
    Instead, we stress the importance of the relationship between GH and fibrosis, and how fibrosis (or lack thereof) might be an emerging factor in both cardiovascular and cancer pathologies. We highlight clinical data from patients with acromegaly or GHD, alongside data from cellular and animal studies, to reveal novel phenotypes and molecular pathways responsible for these actions of GH in fibrosis, cardiovascular function and cancer.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Trial completion:  Acromegaly Combination Treatment Study (clinicaltrials.gov) -  Aug 8, 2022   
    P=N/A,  N=76, Completed, 
    Trial primary completion date: Jul 2022 --> Mar 2022 Recruiting --> Completed
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
    Review, Journal:  Second line treatment of acromegaly: Pasireotide or Pegvisomant? (Pubmed Central) -  Aug 7, 2022   
    According to the high efficacy of these treatments and their molecular mechanisms of action, the choice of second line therapies should be personalized. In this review, we summarize the evidence on clinical, molecular and morphological aspects that may predict the response to second line therapies, in order to integrate and translate in the clinical practice for a patient-tailored therapeutic approach.